Method of diagnosis, prognosis or treatment of neurodegenerative diseases
AssigneesCentre National De La Recherche Scientifique, Universite Paris Est Creteil Val De Marne, Universite Pierre Et Marie Curie (Paris 6), Icm (Institut Du Cerveau Et De La Moelle éPinièRe), Otr3, Assistance Publique-Hopitaux de Paris
InventorsDulce PAPY-GARCIA, Minh Bao HUYNH, Nadia SOUSSI-YANICOSTAS, Rita VOZARI, Fernando SINERIZ, Constantin YANICOSTAS
Life of this patent
Estimating the term…
Abstract
Methods for the diagnosis and prognosis of neurodegenerative diseases, such as a Tauopathy or Alzheimer's disease, are described. Compositions and methods for the treatment of neurodegenerative diseases are also described.
Claims22
A method of treating a neurodegenerative disease, advantageously a Tauopathy, in particular Alzheimer's disease, comprising administering to a subject in need an effective amount of a composition comprising at least one agent which directly or indirectly affects an activity and/or a level of:
- a) at least one gene selected from the group consisting of the nucleotide sequences of SEQ ID NO:
- 1 and SEQ ID NO:
- 3 and coding for an heparin-glucosamine 3-O-sulfotransferase, and/or
- b) at least one transcription product of a gene selected from the group consisting of the nucleotide sequences of SEQ ID NO:
- 1 and SEQ ID NO:
- 3 and coding for an heparin-glucosamine 3-O-sulfotransferase, and/or
- c) at least one translation product of said at least one gene selected from the group consisting of the nucleotide sequences of SEQ ID NO:
- 1 and SEQ ID NO:
- 3, said translation product being of SEQ ID NO:
- 2 and SEQ ID NO:
- 4, respectively, and/or
- d) a fragment or derivative or variant of said gene, transcription product or translation product, and/or
- e) heparan sulfate, in particular the level of 3-O-sulfated heparan sulfate, notably the level of 3-O-sulfated heparan sulfate disaccharide, and/or
- f) abnormal phosphorylation of the Tau protein and/or total Tau protein,
- wherein said neurodegenerative disease is different from a prion disease, and
- wherein when said agent directly or indirectly affects the activity and/or the level:
- of heparan sulfate, or of abnormal phosphorylation of the Tau protein and/or total Tau protein,
- both activities and/or levels of heparan sulfate and of abnormal phosphorylation of the Tau protein and/or total Tau protein are affected by said agent,
- or of at least one other element chosen among said gene, said transcription product of said genes, said translation product of said genes, or said fragment or derivative or variant of said gene or said transcription product or translation product is also affected.
Dependencies are inferred from the claim text.